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STEREOTACTIC BODY RADIOTHERAPY FOR OLIGOMETASTATIC OVARIAN 
CANCER: A STEP TOWARDS A DRUG HOLIDAY 
SUMMARY 
This study including 82 patients showed that stereotactic radiotherapy for oligometastatic ovarian 
cancer is feasible, well tolerated and offers high local control. At 1 year, 1 out of 3 patients is free 
of progression and new treatments.   
ABSTRACT  
Purpose: To evaluate stereotactic body radiotherapy (SBRT) for metachronous oligometastatic 
ovarian cancer patients in terms of local control, delay of systemic treatment, survival outcomes and 
toxicity. 
Materials and Methods: Retrospective data collection from a single institution. Inclusion criteria 
were: (1) oligorecurrent/oligoprogressive disease in ovarian cancer patients after/during systemic 
therapy; (2) surgery/other local therapies not feasible; (3) relative contraindication to systemic 
therapy, no more chemotherapy lines available or refusal of the patient. Tumor response and 
toxicity were evaluated using the Response Evaluation Criteria in Solid Tumors and the Common 
Terminology Criteria for Adverse Events (CTCAE) v4.03, A new systemic therapy regimen was 
started after SBRT treatment course in 57/109 cases (52.3%).respectively. Local progression free 
survival (LPFS), progression free survival (PFS) and overall survival (OS) were calculated via 
Kaplan-Meier method. Systemic treatment free interval (SFI) was calculated in cases without 
concomitant systemic therapy. 
Results: Between May 2012 and December 2016, 82 patients/156 lesions underwent SBRT with a 
median dose of 24 Gy/3 fractions. Median follow-up was 17.4 months. Patients received a median 
of 3 systemic therapy regimens prior to SBRT. Concomitant systemic therapy was performed for 29 
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lesions (18.6%). Complete radiologic response, partial response, stabilization and progressive 
disease were observed in 91 (60%), 26 (17%), 24 (16%) and 11 (7%) lesions, respectively, out of 
152 evaluable lesions. No G3-G4 acute or late toxicities were observed. Median SFI after SBRT 
was 7.4 months and 1 out 3 patients was disease free at 1 year after SBRT. Actuarial 2-year LPFS, 
PFS and OS rates were 68%, 18% and 71%, respectively. Pattern of failure was predominantly out-
field. 
Conclusions: SBRT for oligometastatic ovarian cancer showed good local control and toxicity 
profile. It might be an appealing alternative to other invasive local therapies in order to delay 
systemic therapy in case of chemorefractory disease or intolerance to systemic agents.  
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INTRODUCTION  
Ovarian cancer is the most lethal gynecological cancer.  The role of radiotherapy (RT) remains 
controversial [1]. While whole abdominal irradiation (WART) is no longer considered a suitable 
adjuvant treatment due to unproven efficacy and relevant toxicity,  indication to RT is mainly 
limited to the palliative setting. [2]. Recently, selective approaches with volume-directed involved-
field radiotherapy (IFRT) showed promising results in case of limited recurrent disease [3-9]. The 
availability of more sophisticated imaging and the refinement of RT technology has allowed for the 
delivery of progressively higher doses to comparatively smaller target volumes with ablative-intent 
stereotactic body radiotherapy (SBRT). Oligometastatic state (up to 3-5 detectable metastases) is a 
transitional state between localized and widespread systemic disease in which local control may 
yield improved systemic control [10]. So far, SBRT applications have been incorporated in 
treatment algorithms for multiple disease sites (i.e. lung, prostate, breast) with  local control rates 
ranging between 80 and 90% and excellent toxicity profile [11-16]. To the best of our knowledge, 
no dedicated report on SBRT for ovarian cancer has been published, the only available data 
deriving from oligometastatic patient series including all gynecological malignancies [17-22]. In 
this report we retrospectively reviewed our experience of SBRT for oligometastatic ovarian cancer 
patients in order to evaluate tumor outcome including post-SBRT systemic treatment free interval 
and toxicity. 
METHODS AND MATERIALS  
Study Protocol and Patient selection 
This is a retrospective analysis of a series of oligometastatic ovarian cancer patients treated with 
SBRT at the Radiation Oncology Department of the XXXXXXXX. The study was part of a wider 
SBRT and image-guided RT research notified to the Ethical Committee of the XXXXXXXX 
(notifications 93/11 and 86/11). 
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Indication to SBRT was given following multisciplinary discussion during the institutional tumor 
board for gynecologic malignancies, according to the following criteria: (1) histologically-proven 
primary ovarian cancer; (2) oligorecurrent/oligoprogressive disease (< 5 new or enlarging 
metastases in an otherwise well-controlled disease state); (3) oligopersistent disease (< 5 persistent 
lesions after systemic therapy); (4) salvage surgery/other local therapies not feasible; (5) relative 
contraindication to further systemic therapy due to serious comorbidities, previous severe toxicity, 
no more chemotherapy lines available or refusal of the patient; (6) written informed consent for 
treatment and (7) for the use of the anonymized data for research or educational purpose. Patients 
with  either bone or brain metastases were excluded. 
The diagnosis was based on clinical examination and imaging studies. Total body staging included 
computer tomography (CT) or [18F] fluoro-deoxy-glucose positron emission tomography/CT scan 
(PET/CT). According to TNM classification [23], disease localization was divided in 2 categories: 
regional lymph node (LN) or distant metastasis (M).  
All patients underwent debulking surgery at first diagnosis, and all except one had received 
systemic therapy prior to RT (chemotherapy, biological agents, target therapy or endocrine 
therapy). Additional surgical instances, thermoablation sessions or RT courses for other lesions 
were allowed and did not constitute exclusion criteria for the current study.  
SBRT procedures 
SBRT was performed using VERO™ and Cyberknife™ systems. All patients underwent supine CT 
simulation using suitable immobilization devices according to the site of the lesion. A iodinated 
contrast medium was administered prior to the CT simulation scan, patients with clinical 
contraindication to contrast medium as defined as per our institutional protocol underwent non 
contrast-CT examination. Additionally, whenever feasible, fusion PET/CT was performed with the 
same immobilization system used for CT simulation. In case of lung metastases, CT simulation 
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required a 4D acquisition for real time monitoring of the respiration signal. For all patients, 
simulation and SBRT were performed under free breathing. 
For Cyberknife™ SBRT, the Multiplan treatment planning system (version 2.0.5, Accuray, 
Sunnyvale, CA) was employed. Xsight® Spine (Accuray, Sunnyvale, CA) detecting system was 
used. All patients were immobilized during CT simulation and SBRT bya customized external 
vacuum-type cast. The gross tumor volume (GTV) was contoured on the CT scan and a 2-mm 
margin was added to the GTV to obtain the planning target volume (PTV). The dose was prescribed 
to the 75-80% isodose using a nonisocentric and noncoplanar technique with 6 MV photons. 
For VERO™ SBRT planning, Iplannet (version 4.5.3; BrainLab, Munich, Germany) was used. All 
patients were immobilized during CT simulation and SBRT using the Combifix (CIVCO Medical 
Solutions, Kalona, Iowa, Unites States of America) device with 7 infrared markers on the chest or 
abdomen wall. The GTV was contoured on the CT scan and a 3-mm margin was added to the GTV 
to compensate for the geometrical penumbra of the system. Treatment plans consisted of one or 
more noncoplanar 6MV photons dynamic arcs or multiple modulated fixed beams obtained with the 
micro-multileaf collimator (BrainLAB, Munich, Germany). Cone-beam CT (CBCT) was performed 
before every treatment session;, ExacTrac (BrainLab, Munich, Germany) system was used during 
beam delivery to monitor the position of patient on the basis of the infrared markers. 
Dose volume histograms (DVHs) were calculated for PTV and organs at risk (OARs). The OARs 
constraints for SBRT published by Timmerman et al were applied in all treatment plans [24]. For 
patients who had received prior RT courses, the original treatment plans were retrieved in every 
case of suspected overlap with previous RT fields.. SBRT was usually given every other day. 
After SBRT, patients were seen every 2-4 months either by a Radiation Oncologist or by a 
Gynecologic Oncologist, performing routine periodic re-evaluation with CT or PET/CT and tumor 
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markers dosage. Additional radiologic or PET/CT re-evaluation was requested in case of 
biochemical progression/clinical suspicion of disease progression. 
Evaluation of outcomes and statistical methodology 
Radiological response after SBRT was evaluated by the same imaging modality used for treatment 
planning (CT scan or PET/CT scan) and classified according to Response Evaluation Criteria in 
Solid Tumors (RECIST) v1.1 or PET/CT Response Criteria in Solid Tumors (PERCIST) [25,26]. 
Local disease relapse within the SBRT PTV was defined as in-field progression; distant disease 
relapse or relapse in proximity but outside the SBRT PTV was scored as out-field progression. 
Conversely, out-field LN relapses were dichotomized as either regional (i.e.: pelvic relapse after 
pelvic lymphnode treatment or paraortic relapse after paraortic lymphnode treatment) or 
extraregional (if relapse was outside the region treated with SBRT).   
Patient characteristics were represented as frequencies and percentages for categorical variables and 
medians and ranges for continuous variables.  The length of follow-up was calculated from the last 
SBRT day to the last follow-up visit. Progression free survival (PFS) was defined as the time 
interval between the last day of SBRT and the first diagnosis of progressive disease (any type of 
progression) or the last follow-up visit, in case no signs of progression were found. In-field 
progression free interval (local progression free survival: LPFS) and overall survival (OS) were 
calculated.  
Systemic treatment free interval (SFI) was determined in patients without concomitant systemic 
therapy. It was the time between the last SBRT day and the date of initiation of new systemic 
therapy or the last follow-up visit, if no systemic therapy was started after SBRT. Treatment 
toxicity was evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v4.03 
[27].    
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Univariate and multivariate analyses were performed to quantify the impact of patient-, tumor-, and 
treatment-related factors on clinical outcomes. We carried out Log-rank tests and multivariate Cox-
regression models, taking into account time-dependent variables. Several patients and tumor 
characteristics, recognized prognostic factors, previous treatments modality and RT parameters (i.e.  
Karnofsky Performance Status; treatment site; GTV volume in cm3; biologically effective dose, 
BED) were evaluated in association with clinical outcome. Survival curves were estimated using the 
Kaplan-Meier method. All P-values were set at 0.05. Statistical analyses were performed with the 
SAS statistical software (version 9.2; SAS Institute Inc, Cary, NC). 
RESULTS  
Patients and disease characteristics 
Between 5/2012 and 12/2016, 82 consecutive patients (156 lesions) were treated.  Median age at the 
time of SBRT was 60.4 years (Tab. 1). Primary histologies included high grade serous cell 
carcinoma, low serous cell, endometrioid, granulosa cell and other in 67%, 7.3%, 8.5%, 8.5% and 
8.5% of cases, respectively. Information about breast cancer genes mutation status was available for 
33 patients (40%). Patients received a median of 3 systemic therapy regimens prior to SBRT (range 
0-9). 
Treatment 
Fifty-eight patients (70.7%) underwent a single SBRT course; of these, 41 (72%) had a single 
lesion, while in 16 (28%) more than 1 lesion (2 - 4) were treated concomitantly (synchronous 
SBRT) (Tab. 1). Twenty-four patients (29.3%) received metachronous SBRT: in 21 (25.6%) and 3 
(3.7%) patients, 2 and 3 SBRT were performed at different timing, respectively. In 77 (70.6%) and 
32 (29.4%) SBRT courses, treatment was delivered either  on a single lesion or synchronously on 
more than 1 lesion, respectively. For the whole cohort of patients, we evaluated overall 109 SBRT 
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courses/156 treated lesions. Median dose prescription was 24 Gy (14 - 45 Gy) given in 3 fractions 
(range 1 - 5); median Biologically Effective Dose was 43.2 Gy (range 28-112.5 Gy). Mean GTV 
was 6.77 cm3 (range 0.19– 90.5 cm3) (Tab. 2). 
Follow-up 
No patient was lost at follow-up. Median follow-up was 17.4 months (range 2.2– 51.4 months). At 
the time of the analysis, 28 (34.1%) patients were alive with no evidence of disease, 40 (48.8%) 
were alive with clinically evident disease, and 14 (17.1%) patients had died of disease.  
Treatment Outcome 
Response 
First radiological evaluation was available in 152/156 (94.4%) lesions. PET/CT was performed in 
101/152 lesions (66%) As far as concerned responses classified as progression or stable disease, 
these were confirmed by PET in 17/35 lesions (49%). Response could not be assessed for three 
lesions since the patient had died before re-staging, while the remainder lesion could not be 
properly evaluated because of confounding uptake in the nearby bowel at the first PET/CT scan (but 
evaluable at subsequent follow-up). Complete radiological response, partial response, stabilization 
and progressive disease were observed in 91 (59.9%), 26 (17.1%), 24 (15.8%), 11 (7.2%) evaluable 
lesions, respectively. Median time to any progression was 5.6 months (95% Confidence Interval 
(CI) 3.5– 10.6) (Fig. 1). Actuarial 1 year- and 3 year-PFS were 34% and 8%, respectively. Pattern 
of failure was mainly out-field (Tab. 3). At last follow-up, in-field control was observed in 115 out 
of 153 evaluable lesions (75.2%). Actuarial 1-year and 3-year LPFS rates were 82% and 55%, 
respectively (Fig. 2). 3-year OS rate was 71% (Fig. 3). Loco-regional control was assessed for all 
the 78 treated LN lesions. At last follow-up, loco-regional control was maintained in 47/68 lesions 
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(60%); while disease progressions were distributed as follows: 7/31 cases were regional progression 
only (22%) and 24 were re-staged as both regional and extra-regional progressions (78%). 
In multivariate analysis, PFS was significantly better in cases of absence of residual tumor at first 
surgery (p=0.03, Hazard Ratio (HR) 0.54, 95% CI 0.30 – 0.99). while progression was significantly 
associated with the number of pre-SBRT systemic therapy lines.  
Stage at primary diagnosis, number of SBRT-treated lesions, stage of SBRT-treated lesion (LN vs 
M), and time from last systemic therapy regimen before SBRT were associated with LPFS at 
univariate and multivariate analysis. In-field relapse risk was significantly associated with higher 
stage at diagnosis (III-IV versus I-II, p=0.0008, HR 7.49, 95% CI 2.32 – 24.16), number of treated 
lesions (p=0.0002, HR 2.02, 95% CI 1.39 – 2.92) and stage of SBRT-treated lesion, with M 
including non-locoregional LN versus regional LN (p=0.0008, HR 3.37, 95% CI 1.66– 6.84) (Tab. 
4). Time interval from the last chemotherapy of more than 7 months was associated with a better 
local control (p=0.02), also in a multivariate time dependent Cox regression model (p=0.02).  
Deferral of systemic treatment: 
A new systemic therapy regimen was started after SBRT treatment course in 57/109 cases (52.3%). 
For the SBRT with no concomitant systemic therapy, median SFI was 7.4 months (range 2.1– 49.3). 
In 26 cases (33.3%)/23 patients (28%), systemic therapy was deferred by at least 1 year. 
Considering the 22 patients who received concomitant systemic therapy (either hormonotherapy, 
chemotherapy or maintenance biological agent), indication to a new treatment regimen was given in 
12 cases (55%), while 9 could maintain the ongoing regimen (41%). Of these, systemic treatment 
was interrupted in 3/9 cases (at 12 months after SBRT in 2 patients and after 6 months in 1): all of 
them were disease-free at last follow-up. Information on further systemic therapy was not available 
for 1/22 patient (4%).  
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Toxicity 
SBRT was well tolerated. In 57 patients (69.5%) no acute or late toxicities were observed. No G3-
G4 acute or late events were observed. Acute toxicity observed in 22 patients included G1-G2 
gastrointestinal events (17 patients) and G1 fatigue (5 cases). Late toxicity (23 cases) included G1-
G2 gastrointestinal events (16 patients), G1 genitourinary (4 events), other G1 events in 3 cases. 
DISCUSSION 
To the best of our knowledge, this is the largest series on oligometastatic ovarian cancer patients 
treated with SBRT. Our data show that SBRT may provide good local control, with more than one-
third of patients being disease-free at 1 year. Moreover, we could achieve an interestingly durable 
systemic therapy free interval, which was especially relevant for heavily pre-treated patients or for 
those who had shown poor tolerance to chemotherapy. Additionally, not only toxicity rates were 
extremely low, but SBRT re-treatment may be proposed in case of further oligometastatic 
progression.    
After it was first proposed in 1995 by Hellman and Weichselbaum [28], the concept of 
oligometastatic disease has been progressively investigated. The recognition of a continuous rather 
than a bimodal metastatic state (loco-regionally vs widely disseminated disease), with a distinct 
biological pattern and clinical outcome, has opened doors to the application of focal therapies in this 
subset of patients. In this context, SBRT has come to attention as a non-invasive alternative to 
surgery in the management of oligometastases, and a recent multi-national survey has endorsed its 
use with a strong level of recommendation [29] in cases with up to five metastases (range 2-5, 
limiting to three the number of lesions within a single organ).  The potential role of SBRT in 
deferring systemic therapy has already been investigated in other  oligometastatic tumors, with the 
concept of “drug holiday” or “androgen deprivation therapy (ADT)-free survival” [14,30-32]. 
Conversely, gynecological malignancies remain a largely unexplored field for SBRT applications in 
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the oligometastatic/oligorecurrent setting. Many published series include multiple subsites, and in 
only two SBRT studies ovarian cancer represent at least 50% of the selected population [20,22]. In 
our series of ovarian cancer patients, median SFI was  7.4 months. The longest SFI was 49.3 
months with freedom from systemic therapy at 1 year in almost 30.5% of cases. Median SFI raised 
up to 13 months (range 6.3– 49.3 months) with a 1 year-deferral of systemic treatment in almost 
58% of cases when SBRT was followed by other local therapies (including additional SBRT 
courses). This approach could also give a later possibility of rechallenge with cytotoxic systemic 
agents, enhancing therapeutic chances in these patients. In the current SBRT study, we chose to 
apply the linear quadratic (LQ) model. Although no direct data have been published on ovarian 
cancer series, the existing literature seems to support the validity of the LQ model for doses up to 
18 Gy/fraction [33].  
Our results permit to overcome the paradigm of the exclusive palliative role of RT in recurrent 
ovarian cancer, adding strength to the concept, previously introduced with IFRT, of RT as an active 
and definitive treatment option, to be integrated in a multidisciplinary strategy in order to 
maximally improve patients’ clinical outcomes. Previous IFRT studies for limited recurrent ovarian 
cancer considered a variety of RT techniques and employed median doses of 45–60 Gy with either 
conventional fractionation or moderate hypofractionation.  Albuquerque et al. [4] demonstrated that 
5 years after IFRT high rates of local control  (LRFS 70%) with a disease free survival (DFS) 33%. 
As already discussed by Chundury et al. [5], these results can be influenced by the fact that a high 
proportion of patients had previous optimal debulking of treated lesions or complete response to 
chemotherapy. The same authors have recently investigated the use of intensity modulated 
radiotherapy (IMRT) showing 2- and 3-year DFS of 11% and 8%, respectively, which are similar to 
our corresponding PFS rates (18% and 8%), while achieved a comparatively higher 3-year LPS 
(72% vs  55% in our series) [5]. Yahara et al. [6] found after external RT or brachytherapy a 3 year- 
LPFS of 96% and a 3 year- PFS of 39%, including in their analysis only patients with up to 2 
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lesions after ≤ 3 chemotherapy regimens. Interestingly, our analysis confirmed the significant 
association between these parameters and better LPFS and PFS. With the important limitation of 
making a comparison between such different techniques, doses and fractionations, we can assume 
that SBRT could be a reasonable alternative to IFRT, with the additional advantage of a very short 
overall treatment time.  
Kunos et al. [20] in their phase II study demonstrated a 100% local control rate and a median DFS 
of 7.8 months, using a dose prescription of 24 Gy in 3 fractions. Mesko et al. [22] found a median 
DFS of 10.8 months and a local control rate of 83%, using median prescription doses between 32.5 
Gy in 5 fractions and 50 Gy in 4 fractions. Our local control rate (75%) and median PFS (5.64 
months) were slightly lower when compared to both IFRT series and to Kunos’ and Mesko’s SBRT 
studies. Firstly, this might be at least partially explained by median dose of 24 Gy in 3 fractions 
which is lower than that prescribed by Mesko and in other IFRT series. This may underline the need 
of dose escalation [34-36], especially for the treatment of distant metastases (which were 50% of 
targets in our series, treated with the same median dose of 24 Gy in 3 fractions as loco-regional LN, 
but reaching lower local control rate of 70% vs. 81%). Corbin et al. reported that doses of either 50 
Gy in 5 or 10 fractions or 36–48 Gy in 3 fractions yielded superior local control rates than 24–30 
Gy in 3 fractions [34]. In our study, all distant metastasis treated with 36–45 Gy kept in field-
control until last follow-up, while those treated with less than 36 Gy only in 65% of cases. 
Definitely, low toxicity and in-field progression observed in some patients open space for dose 
escalation. Differences in patient selection can also explain the difference between our findings and 
Kunos’ results, Indeed, the majority of Kunos series patients had no prior systemic therapy (56%), 
were treated on ≤ 2 lesions (70%) and on loco-regional LN (66%). The latter feature in our study 
correlated with significantly better outcome: large part of patients with a PFS of at least 1 year were 
treated on a single lesion (90%),  underwent 2 or less pre-SBRT systemic therapy regimens (63%) 
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and were treated on LN (74%), which were loco-regional LN (53%) and distant LN (21%). An 
overview of the currently available literature, as previously discussed, is provided in Table 5.  
Our patients were widely heterogeneous (histological subtype, prior treatments, number of lesions). 
In several cases, they were referred to SBRT after the failure of multiple lines of systemic agents or 
when limited disease persisted after a previous polymetastatic state (negatively selected patients). 
Therefore we can hypothesize that a subgroup of patients, despite the low burden of disease at the 
time of SBRT, may not have been in a truly oligometastatic state and microscopic disease could  
have already become disseminated. Our analysis confirmed better outcomes in those patients with 
disease characteristics associated with limited-burden disease (presentation stage I-II, no residual 
tumor at first surgery, fewer previous systemic regimens performed, ≤ 2 lesions treated, only loco-
regional LN involvement, time from last chemotherapy cycle > 7 months), thus strengthening the 
need for accurate patient selection and disease staging prior to the beginning of SBRT. We are well 
aware of the limitations of our study, which are mainly inherent to its retrospective nature (i.e. 
patient selection, potential under-reporting of toxicities). Additionally, as the proportion of patients 
who were re-staged with PET/CT was relatively high (66%), we acknowledge a possible 
underestimation of disease progression rates for those having PET-negative disease.  Nevertheless, 
we could demonstrate that SBRT can be considered as a feasible and potentially effective treatment 
in the setting of oligometastic/oligorecurrent ovarian cancer. The identification of common patient 
selection criteria, together with the definition of fractionation and adequate treatment timing, are 
warranted in the upcoming future. Arguably, the incorporation of such parameters in structured 
prospective studies should contribute to improve the level of evidence of SBRT for ovarian cancer 
patients, and to break the paradigm of RT as a solely palliative treatment modality in this clinical 
scenario.  
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SBRT in oligometastatic/oligoprogressive ovarian cancer is safe and feasible and provides good 
local control at extremely low toxicity. In a good proportion of patients SBRT can allow for lasting 
treatment and toxicity free interval. Further prospective studies are warranted to identify which 
subgroup of patients may most benefit from this treatment. We believe that this experience could 
constitute a benchmark for SBRT application in oligorecurrent/oligoprogressive ovarian cancer and 
serve as well as an hypothesis-generating study for further clinical efforts. Specifically, the 
development of a prospective institutional trial is underway in order to help enhance the therapeutic 
index of SBRT (i.e. through the use of patient-reported-outcome tools) in a population of comorbid, 
heavily pretreated patients.  
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Table 1. Patient, tumor and treatment characteristics (N=82 patients, n= 156 lesions, n=109 SBRT 
courses) 
 
Patient, tumor and treatment characteristics n (%) 
Age (range)  
Median (range) 
 
60.4 (37.5-84.13) 
Karnofsky Performance Status 
 60 - 80 
 90 
 100 
 
5 (6) 
18 (22) 
59 (72) 
Primary histology  
 Serous-high grade 
 Serous-low grade 
 Endometrioid 
 Granulosa cell tumor 
 Other  
 
55 (67.1) 
6 (7.3) 
7 (8.5) 
7 (8.5) 
7 (8.5) 
Grade  
 1 
 2 
 3 
 4 
 Unknown 
 
2 (2.4) 
11 (13.4) 
60 (73.2) 
1 (1.2) 
8 (9.8) 
FIGO stage at diagnosis  
 I 
 II 
 III 
 IV 
 Unknown 
 
6 (7.3) 
11 (13.4) 
52 (63.4) 
12 (14.6) 
1 (1.2) 
BRCA status  
 Negative  
 BRCA1 positive  
 BRCA2 positive  
 Unknown 
 
18 (22) 
8 (9.8) 
7 (8.5) 
49 (59.6) 
Baseline Platinum Sensitivity  
 Sensitive (PFI > 12 months): 
 Partially sensitive (PFI: 6 – 12 months): 
 Resistant/Refractory (PFI: <6 months): 
 
48 (58.5) 
24 (29.3) 
10 (12.2) 
Number of SBRT treatment courses per patient during time  
 1  
 2 
 3 
 
58 (70.7) 
21 (25.6) 
3 (3.7) 
Number of treated lesions per treatment course  
 1 
 2 
 3 
 4 
 
77 (70.6) 
22 (20.2) 
5 (4.6) 
5 (4.6) 
Number of treated lesions (per patient)  
 1 
 2 
 3 
 ≥4 
 
40 (49) 
23 (28) 
11 (13.4) 
8 (9.6) 
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Interval between diagnosis of primary tumor and SBRT  
 Mean (range) in years 
 Median 
 
6.31 (0.48-22.3) 
5.21 
Treatment characteristics prior to SBRT n (%) 
Previous treatments: 
 Surgery 
 Chemotherapy/biological agents  
 Endocrine therapy 
 Thermoablation   
 RT for ovarian cancer 
 RT only for previous breast cancer 
 
82 (100) 
81 (98.8) 
20 (42.4) 
4 (4.9) 
19 (23.2) 
5 (6.1) 
Number of previous systemic therapy regimens  
(median; range) 
 
3 (0 – 9)  
Platinum-based chemotherapy regimens  
(median; range) 
 
2 (0 – 6)  
Number of surgical instances  
(median; range)  
 
1 (1 – 7) 
Pre-SBRT Platinum Sensitivity 
 Sensitive (PFI > 12 months) 
 Partially sensitive (PFI 6 – 12 months) 
 Resistant/Refractory (PFI < 6 months) 
 
36 (33) 
36 (33) 
37 (34) 
 
Abbreviations: BRCA: Breast Cancer Gene; FIGO, International Federation of Gynecologists and 
Obstetrics;  PFI, platinum free interval; RT, Radiotherapy; SBRT, Stereotactic Body Radiotherapy 
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Table 2. SBRT Treatment characteristics by lesions (n=156) 
 
Characteristics n (%) 
Classification of SBRT-treated lesion  
 Oligorecurrent 
 Oligoprogressive 
 Oligopersistent 
 
78 (50) 
47 (30 ) 
31 (20) 
SBRT treatment  
 VERO system (Mitsubishi-Brainlab)  
 CyberKnife (Accuray)  
 
126 (80.8)  
30 (19.2) 
SBRT treatment group/per lesion 
Abdomen Pelvis 
    Regional lymph node  
    Distant lymph node 
    Visceral metastases 
         Abdominal cavity: 14 lesions 
          Liver: 14 lesions 
          Other: 2 lesions 
Thorax 
    Distant lymph node 
    Visceral metastasis:  
           Lung: 6 lesions 
           Pleura: 8 lesions 
Head and Neck  
 
 
123 (79) 
78 
15 
30 
 
 
 
26 (17) 
12 
14 
 
 
7 (4) 
Previous radiotherapy in the site of treated lesion  
 Yes 
 No 
 
5 (3.2) 
151 (96.8) 
Concomitant systemic therapy/per lesion  
 No  
 Yes 
  Chemotherapy 
  Endocrine therapy 
 
127 (81.4) 
29 (18.6) 
9 (5.8) 
20 (12.8) 
Number of fractions  
Median, range 
 
3 (1 - 5) 
Total dose and fractionation/per lesion  
 24 Gy (8 Gy x 3 fr) 
 25 Gy (5 Gy x 5 fr) 
 30 Gy (10 Gy x 3 fr) 
 Other regimens 
 
89 (57) 
 35 (22.4) 
10 (6.4) 
22 (14.1) 
BED in Gy (α/β=10 Gy) 
 Median 
 Range 
 
43.2 
28 – 112.5 
GTV volume (cm
3
)
 
 Mean  
 Median 
 Range  
 
6.77 
3.15 
0.19 – 90.5 
 
Abbreviations: BED, Biologically Effective Dose;  GTV, Gross Tumor Volume; LN, regional lymph nodes; M, 
distant metastases; SBRT, Stereotactic Body Radiotherapy 
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Table 3. SBRT Treatment outcome (n= 82 patients, n=156 lesions) 
 
Outcome  n (%) 
Follow-up duration, months  
Median (range) 
 
17.4  (2.2– 51.4) 
Status at the last observation (December 2016, n=82 patients) 
 NED   
 AWD 
 Died of disease 
 
28 (34.1) 
40 (48.8) 
14 (17.1) 
Radiological and/or FDG-PET/CT response to SBRT at first assessment (n=156 lesions, 
152 evaluable): 
CR 
PR 
SD 
PD 
 
 
91 (59.9) 
26 (17.1) 
24 (15.8) 
11 (7.2)  
Radiological and/or FDG-PET/CT response in the lesions treated with SBRT only with no 
concomitant systemic therapy (n=127 lesions, 123 evaluable) 
 CR 
 PR 
 SD  
 PD 
 
 
76 (61.8) 
17 (13.8) 
19 (15.5) 
11 (8.9) 
Disease progression after first SBRT course (n=82, 81 evaluable) 
 Yes  
 No  
 
60 (74.1) 
21 (25.9) 
Site of first progression (n=60) 
 In-field only   
 Out-field only 
 In-field+ Out-field 
 
2 (3.5) 
54 (90) 
4 (5.5) 
In field progression (at any time)/per lesion (n=153) 
 Yes 
 No 
 
38 (24.8) 
115 (75.2) 
Local control at last follow-up (n= 153) 
 Yes 
 No 
 
115 (75.2) 
38 (24.8) 
Local control at last follow-up in the lesions treated with SBRT only with no concomitant 
systemic therapy (n=127, 124 evaluable): 
 Yes 
 No 
 
 
90 (72.6) 
34 (27.4) 
Systemic treatment free-interval (months) after SBRT courses with no concomitant 
systemic therapy: 
 Mean, Median 
 Range 
 
 
10.5 ,7.4 
2.1 – 49.3 
Systemic treatment free-interval (months) after single SBRT courses not followed by 
intermediate SBRT/other local therapies before new systemic regimen or last follow-up: 
 Mean, Median  
 Range 
 
 
9, 6 
2.1 – 33.4 
Systemic treatment free-interval (months) after SBRT courses followed by intermediate 
SBRT/other local therapies (on different disease sites) before new systemic regimen or 
last follow-up: 
 Mean, Median  
 
 
 
15.8, 13 
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 Range 6.3 – 49.3 
Abbreviations: AWD, Alive With Disease; CR, Complete Response; FDG-PET/CT, [
18
F]-fluoro-deoxy-glucose 
positron emission tomography/computer tomography scan; NED, Non Evidence of Disease; PD, Progression 
of Disease; PR, Partial Response; SD, Stable Disease; SBRT, Stereotactic Body Radiotherapy. 
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Table 4. Multivariate regression Cox models for progression 
 
Analyses Variables included in the model          HR Low 95%CI Up 95%CI P-values 
Per patients Residual tumor at first surgery  0.54 0.30 0.99 0.05 
      
Per lesions Rtage III-IV vs I-II 7.49 2.32 24.15 0.0008 
 
N. of treated lesions 2.02 1.39 2.9 0.0002 
 
M vs LN 3.37 1.66 6.84 0.0008 
 
Time from the last chemotherapy 
>7months 2.39 1.18 4.84 0.016 
 
Abbreviations: CI: Confidence Interval; HR: Hazard Ratio; LN, regional lymph nodes; M, distant metastases; 
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TABLE 5. Published clinical series including patients treated with radiotherapy for oligorecurrent/oligoprogressive ovarian cancer 
 
Author, year of 
publication 
Ref n Primitive Site of 
Disease 
Pre-RT 
chemotherapy 
courses, median 
(range) 
Site of 
recurrence 
RT modality Total Dose 
(median) 
Median 
follow-up 
(range) 
PFS LRFS OS 
Brown et al, 2013 3 102 Ovary: 100% 3 (0-9) Nodal: 49% pts 
Extranodal: 51% 
IFRT Definitive IFRT: 
59.2 Gy (73 pts) 
 
Post-operative: 
54.5 Gy (16 pts) 
 
Post-induction 
CT (13 pts)   
37 (1-123) 
months  
5-year: 24%, 
38% pts 
without ED at 
after a median 
f-up of 38 
months 
(range:7-122) 
5-year: 71% 5-year: 
40% 
Albuquerque et 
al, 2016 
4 27 Ovary: 100% 10 Extraperitoneal 
local recurrences 
EBRT only: 
18 pts (67%) 
 
EBRT+BRT: 
7 pt (26%) 
 
BRT only: 2 
pts (7%) 
50.4 (40-60) Gy 
 
Post- R0/R1 
surgery: 17 pts; 
Salvage/Post 
R2 surgery: 10 
pts) 
 
2.5 years 5-year 
(actuarial): 33% 
5-year 
(actuarial):70%  
5-year 
(actuarial): 
30% 
Chundury et al, 
2016 
5 33 pts, 
49 
lesions 
Ovary: 100% 3 (1-12) Abdomen/pelvis: 
34 pts (69.4%) 
 
Thorax: 3 pts 
(6.1%) 
 
Other sites: 12 
pts (24.5%) 
IMRT 50.4 (45-70) Gy 23.7 (1.0-
105.8) 
months 
2-year 
(actuarial): 11% 
2-year 
(actuarial): 
82% 
2-year 
(actuarial): 
63% 
Yahara et al, 
2013 
6 27 pts Ovary: 100% Not stated Abdomen/pelvis EBRT only 
(3D-CRT): 25 
pts (93%) 
 
EBRT+BRT: 
1 pt (4%) 
 
BRT only: 1 
pt (4%) 
60.0 (50.0-61.2) 
Gy 
25 (3-95) 
months 
(surviving 
pts) 
2-year: 39% 2-year: 96% 2-year: 
56% 
Kunos et al, 2012 20 50 pts Ovary: 50% 
Uterus: 28% 
Uterine Cervix: 
18% 
Vulva: 4% 
Not stated Abdomen/pelvis: 
44 pts (88%) 
 
Thorax: 6 pts 
(12%) 
SBRT, 
Cyberknife 
24 Gy, 8 
Gy/fraction 
(mainly to the 
70% isodose 
line)  
15 (1-31) 
months 
7.8 months 
(95% C.I.) 
15-months: 
100% 
20.2 
months 
(95% C.I.) 
Mesko et al, 
2017 
22 28 pts, 
47 
lesions 
Ovary: 15 pts 
Endometrium: 8 
pts 
Cervix: 2 pts 
Vagina: 2 pts 
Carcinosarcoma: 
2 (0-9) Abdomen/pelvis: 
53% 
 
Thorax: 21% 
 
Unspecified: 26% 
SBRT 40 (16-54) Gy 12.8 
months 
10.8 months Not stated Not stated 
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1 pt 
Current study, 
Lazzari&Ronchi 
et al, 2018 
 82 pts, 
156 
lesions 
Ovary: 100% 3 (0-9) Abdomen/pelvis: 
123 pts (79%) 
 
Thorax: 26 pts 
(17%) 
 
Head and Neck: 
7 pts (4%) 
SBRT 24 Gy, 8 
Gy/fraction 
17.4 
months 
2-year 
(actuarial): 18% 
2-year 
(actuarial): 
68% 
2-year 
(actuarial): 
71% 
 
Abbreviations: BRT: Brachytherapy, EBRT: External Beam Radiotherapy, IFRT: Involved-Field Radiotherapy, LRFS. Local Recurrence Free Survival, OS: Overall Survival, PFS: Progression Free 
Survival, Pts: Patient, Ref: Reference, RT: Radiotherapy SBRT: Stereotactic Body Radiotherapy 
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Fig. 1: Kaplan–Meier curve for progression-free survival (PFS) of the 82 patients over time (full line). 
Confidence interval (C.I.)= 95% (dashed line).  
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Fig. 2: Kaplan–Meier curve for local progression free survival (LPFS) of the 153 treated lesions over time 
(full line). Confidence interval (C.I.)= 95% (dashed line).  
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Fig. 3: Kaplan–Meier curve for overall survival (OS) of the 82 patients over time (full line). Confidence 
interval (C.I.)= 95% (dashed line).  
 
